Posters

Endoserter vs endoglide: a comparison of outcomes during Descemet's stripping endothelial keratoplasty

Poster Details

First Author: F.Chew UK

Co Author(s):    M. Sawant   V. Gangwani                 

Abstract Details

Purpose:

There are very few studies comparing the surgical outcomes of the Endoserter technique and the Endoglide technique employed in Descemet Stripping Endothelial Keratoplasty (DSEK). This study aims to compare two different surgical techniques employed using the Endoserter and the Endoglide by evaluating the outcomes of patients best corrected visual acuity (BCVA), endothelial cell loss, post -operative complications and post -operative refraction.

Setting:

This study was performed at Ashford and St Peters eye hospital NHS foundation trust.

Methods:

This was a retrospective study, looking at DSEK operations performed from May 2012 to June 2014, using two different techniques; the endoserter and the Tan endoglide which is employed by two different experienced surgeons respectively. Patient notes were analysed and their pre and post operative outcomes BCVA, endothelial cell counts at 6 months post op and any post operative complications were recorded.

Results:

Of the 20 patients that were evaluated during this period, 13 were operated on using the endoserter technique and 7 using the Tan Endoglide. The mean endothelial cell loss using the endoserter technique was 1181±574, whilst the mean endothelial cell loss using the Tan endoglide was 968±417. Percentage cell loss was 47% and 37% respectively. Patients in the endoserter group had a mean of 0.2 improvement in BCVA compared to 0.07 in the Tan endoglide group. There was a 20% rebubbling rate in the endoserter group compared to 12% compared to the Tan endoglide.

Conclusions:

Our results show that the mean post- operative endothelial cell loss is slightly less in the endoglide group as compared to the endoserter technique, in addition to a lower chance that the graft will need rebubbling at a later stage. However, further studies with more patients over a longer period will be ideal to validate these findings.

Financial Disclosure:

NONE